EichorEICHOR
Condition: Active Systemic Lupus Erythematosus Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Active Systemic Lupus Erythematosus

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
Phase 1/Phase 2 · 1 location(s) · 920th Hospital of Joint Logistics Support Force of People's · NCT06675422Clinical Study of Cizutamig in Systemic Lupus Erythematosus
Phase 1 · 1 location(s) · Candid Therapeutics · NCT07215663A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · 101 location(s) · Novartis Pharmaceuticals · NCT06581198Dapagliflozin in Active Lupus Nephritis
Phase 4 · 2 location(s) · Brigham and Women's Hospital · NCT07323524Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
Phase N/A · 20 location(s) · Monash University · NCT03138941Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
NA · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07470151A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
Phase 2 · 1 location(s) · InventisBio Co., Ltd · NCT07311200NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
Phase N/A · 16 location(s) · AstraZeneca · NCT07424261Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter S
Phase N/A · 1 location(s) · University of Pisa · NCT07215754Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
Phase N/A · 1 location(s) · Cliniques universitaires Saint-Luc- Université Catholique de · NCT05443516Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
Phase 1 · 2 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06400537An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT07174843Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Phase 2 · 103 location(s) · Novartis Pharmaceuticals · NCT05268289A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Act
Phase 3 · 236 location(s) · UCB Biopharma SRL · NCT06617325Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Phase 2 · 14 location(s) · Autolus Limited · NCT07053800Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SL
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06711146AGR+PNI as Predictors of Systemic Lupus Erythematosus Disease Activity
Phase N/A · 1 location(s) · Sohag University · NCT07043153UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
Phase 1 · 1 location(s) · Nanjing IASO Biotechnology Co., Ltd. · NCT07109986RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic
Phase 1/Phase 2 · 23 location(s) · Cabaletta Bio · NCT06121297Effects of High-intensity Interval Training in Patients With Systemic Lupus Erythematosus
NA · 1 location(s) · Karolinska Institutet · NCT06166199RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
Phase 2 · 1 location(s) · Jiangsu Renocell Biotech Company · NCT06058078A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or I
Phase 2 · 43 location(s) · Hoffmann-La Roche · NCT05039619A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
Phase 1/Phase 2 · 1 location(s) · ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. · NCT06535412A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Jap
Phase 1 · 28 location(s) · GlaxoSmithKline · NCT06576271Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
Phase N/A · 22 location(s) · AstraZeneca · NCT07330245SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523542A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Phase 2 · 57 location(s) · Amgen · NCT06570798A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
Phase 1 · 1 location(s) · Hinge Bio · NCT07491900A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
Phase 1 · 7 location(s) · Sanofi · NCT06647069A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06106906
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.